Pneumococcal Vaccine Market by Application, Type, Deployment, Organization Size, Verticals Forecast 2021
Pneumococcal Vaccine Market, has been prepared based on an in-depth market analysis with inputs from industry experts.
(EMAILWIRE.COM, May 26, 2017 ) Pneumococcal Vaccine Market Research Report covers the present scenario and the growth prospects of the Pneumococcal Vaccine Industry for 2016-2020. Pneumococcal Vaccine Market, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years and discussion of the key vendors effective in this market. To calculate the market size, the report considers the revenue generated from the sales of Pneumococcal Vaccine globally.
The Pneumococcal Vaccine Market report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry.
Following Companies Are Key Players of the Pneumococcal Vaccine Market:
GlaxoSmithKline (GSK)
Merck
Pfizer
Sanofi
Other Prominent Vendors of Pneumococcal Vaccine Market Are:
Abera
AstraZeneca
Baxter
Beijing Minhai Biotechnology
Biken
Biogen
“Emergence of protein-based combination pneumococcal vaccines will be a key trend for market growth. There is an increasing number of new pneumococcal protein-based vaccines, which are undergoing clinical trial evaluations. These protein-based vaccines consist of serotype-independent subunit vaccines containing purified proteins and antigens that are expressed by recombinant bacteria. These vaccines will avoid the problems of serotype replacement by directly targeting proteins that are highly preserved among many pneumococcal serotypes.”
Ask Sample PDF of Pneumococcal Vaccine Market Report @ http://www.marketreportsworld.com/enquiry/request-sample/10279693
According to the Pneumococcal Vaccine Market report, availability of global action plans for pneumonia vaccines will be a key driver for market growth. A consultation was held in Geneva in 2006, where WHO, in collaboration with vaccine manufacturers, public health organizations, academic experts, and funding agencies from developed and developing countries, developed the global action plan for pneumococcal vaccine. The plan was intended to combat the global shortage of pneumococcal vaccine. It is a comprehensive strategy focused on increasing the use of the vaccine, and increasing its production capacity and R&D. WHO is working to promote the use of pneumonia vaccines by encouraging its member states to develop a policy for pneumonia vaccination.
Report also presents Geographical Segmentation analysis of Pneumococcal Vaccine Market of Americas, APAC, EMEA region.
Further, the Pneumococcal Vaccine Market report states that inadequate vaccine coverage will be a challenge for the market. The coverage rates for a vaccine indicate the level of acceptance and extent of immunization for that vaccine. Negligence and lack of awareness among individuals, despite the subsidies offered by the government, is a major factor decreasing these coverage rates. Studies have estimated that the total global PCV coverage was at 19% in 2014. Studies also say that the coverage was 20% among the adults aged 19-64 years in 2013 in the US. The vaccination rate was higher in the adults aged 65 years and above, which was reported at 59.9%. The overall rate for pneumococcus infection was around 17% among vaccine-eligible subjects.
Key questions answered in Pneumococcal Vaccine market report:
What will the Pneumococcal Vaccine market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving Pneumococcal Vaccine market?
What are the challenges to Pneumococcal Vaccine market growth?
Who are the key vendors in Pneumococcal Vaccine market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
Get Report @ http://www.marketreportsworld.com/purchase/10279693
The Pneumococcal Vaccine Market report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry.
Following Companies Are Key Players of the Pneumococcal Vaccine Market:
GlaxoSmithKline (GSK)
Merck
Pfizer
Sanofi
Other Prominent Vendors of Pneumococcal Vaccine Market Are:
Abera
AstraZeneca
Baxter
Beijing Minhai Biotechnology
Biken
Biogen
“Emergence of protein-based combination pneumococcal vaccines will be a key trend for market growth. There is an increasing number of new pneumococcal protein-based vaccines, which are undergoing clinical trial evaluations. These protein-based vaccines consist of serotype-independent subunit vaccines containing purified proteins and antigens that are expressed by recombinant bacteria. These vaccines will avoid the problems of serotype replacement by directly targeting proteins that are highly preserved among many pneumococcal serotypes.”
Ask Sample PDF of Pneumococcal Vaccine Market Report @ http://www.marketreportsworld.com/enquiry/request-sample/10279693
According to the Pneumococcal Vaccine Market report, availability of global action plans for pneumonia vaccines will be a key driver for market growth. A consultation was held in Geneva in 2006, where WHO, in collaboration with vaccine manufacturers, public health organizations, academic experts, and funding agencies from developed and developing countries, developed the global action plan for pneumococcal vaccine. The plan was intended to combat the global shortage of pneumococcal vaccine. It is a comprehensive strategy focused on increasing the use of the vaccine, and increasing its production capacity and R&D. WHO is working to promote the use of pneumonia vaccines by encouraging its member states to develop a policy for pneumonia vaccination.
Report also presents Geographical Segmentation analysis of Pneumococcal Vaccine Market of Americas, APAC, EMEA region.
Further, the Pneumococcal Vaccine Market report states that inadequate vaccine coverage will be a challenge for the market. The coverage rates for a vaccine indicate the level of acceptance and extent of immunization for that vaccine. Negligence and lack of awareness among individuals, despite the subsidies offered by the government, is a major factor decreasing these coverage rates. Studies have estimated that the total global PCV coverage was at 19% in 2014. Studies also say that the coverage was 20% among the adults aged 19-64 years in 2013 in the US. The vaccination rate was higher in the adults aged 65 years and above, which was reported at 59.9%. The overall rate for pneumococcus infection was around 17% among vaccine-eligible subjects.
Key questions answered in Pneumococcal Vaccine market report:
What will the Pneumococcal Vaccine market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving Pneumococcal Vaccine market?
What are the challenges to Pneumococcal Vaccine market growth?
Who are the key vendors in Pneumococcal Vaccine market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
Get Report @ http://www.marketreportsworld.com/purchase/10279693
Contact Information:
Markets Reports World
Ameya Pingaley
Tel: +1 408 520 9750
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
Markets Reports World
Ameya Pingaley
Tel: +1 408 520 9750
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results